<DOC>
	<DOCNO>NCT01468051</DOCNO>
	<brief_summary>Patients chronic renal disease vaccinate soon dialysis forestall could improve seroconversion rate hepatitis B vaccination . In study , investigator aim compare seroconversion rate immune response rate use four dos 40 μg three dose 20 μg Euvax B recombinant hepatitis B surface antigen ( HBsAg ) vaccine give predialysis CKD patient .</brief_summary>
	<brief_title>Two Schedules Hepatitis B Vaccination Predialysis Chronic Renal Failure Patients</brief_title>
	<detailed_description>In open , randomized clinical trial , investigator compare seroconversion rate 51 predialysis patient mild moderate chronic renal failure use either 40 μg 4 dose 20 μg 3 dos Euvax B recombinant hepatitis B vaccine administer 0 , 1 , 2 , 6 0 , 1 , 6 month respectively .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>predialysis patient , &gt; 18 year mild moderate chronic renal failure , serum creatinine 1.56 mg/dl patient severe renal failure , serum creatinine &gt; 6 mg/dl , require dialysis expect require dialysis within 1 year , receive immunosuppressive treatment , know lymphoproliferative disorder .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>predialysed</keyword>
	<keyword>chronic</keyword>
	<keyword>renal failure patient</keyword>
</DOC>